MX2012004259A - Combinacion. - Google Patents
Combinacion.Info
- Publication number
- MX2012004259A MX2012004259A MX2012004259A MX2012004259A MX2012004259A MX 2012004259 A MX2012004259 A MX 2012004259A MX 2012004259 A MX2012004259 A MX 2012004259A MX 2012004259 A MX2012004259 A MX 2012004259A MX 2012004259 A MX2012004259 A MX 2012004259A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- treatment
- relates
- cancer
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940124647 MEK inhibitor Drugs 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229940116355 PI3 kinase inhibitor Drugs 0.000 abstract 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 abstract 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25063509P | 2009-10-12 | 2009-10-12 | |
| PCT/US2010/052242 WO2011046894A1 (en) | 2009-10-12 | 2010-10-12 | Combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012004259A true MX2012004259A (es) | 2012-05-29 |
Family
ID=43876468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012004259A MX2012004259A (es) | 2009-10-12 | 2010-10-12 | Combinacion. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120202822A1 (enExample) |
| EP (1) | EP2488184A4 (enExample) |
| JP (1) | JP2013507442A (enExample) |
| KR (1) | KR20120097496A (enExample) |
| CN (1) | CN102665720A (enExample) |
| AU (1) | AU2010307043C1 (enExample) |
| BR (1) | BR112012008519A2 (enExample) |
| CA (1) | CA2777561A1 (enExample) |
| EA (1) | EA020965B1 (enExample) |
| IL (1) | IL219103A0 (enExample) |
| MX (1) | MX2012004259A (enExample) |
| WO (1) | WO2011046894A1 (enExample) |
| ZA (1) | ZA201202416B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013545756A (ja) * | 2010-11-16 | 2013-12-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | 投与および治療方法 |
| SG11201500321YA (en) * | 2012-08-07 | 2015-04-29 | Novartis Ag | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
| HK1206605A1 (en) | 2012-08-17 | 2016-01-15 | 霍夫曼-拉罗奇有限公司 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
| CN103936728B (zh) * | 2013-01-18 | 2016-08-10 | 通化济达医药有限公司 | 噻唑激酶抑制剂 |
| CN103936730A (zh) * | 2013-01-22 | 2014-07-23 | 通化济达医药有限公司 | 苯磺酰胺噻唑激酶抑制剂 |
| CN103965180B (zh) * | 2013-01-24 | 2016-09-07 | 通化济达医药有限公司 | 苯磺酰胺噁唑和噻唑激酶抑制剂 |
| US20150352121A1 (en) * | 2013-03-12 | 2015-12-10 | Glaxosmithkline Llc | Combination |
| EP2976106B1 (en) | 2013-03-21 | 2021-04-14 | Array BioPharma Inc. | Combination therapy comprising a b-raf inhibitor and a second inhibitor |
| CN104540822B (zh) * | 2013-07-08 | 2016-08-31 | 杭州普晒医药科技有限公司 | 达拉菲尼甲磺酸盐的晶型及其制备方法 |
| EP4062917B1 (en) * | 2013-12-20 | 2025-12-03 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440966B1 (en) * | 1999-01-13 | 2002-08-27 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as MEK inhibitors |
| US7691377B2 (en) * | 2004-04-16 | 2010-04-06 | Rutgers, The State University Of New Jersey | Methods and compositions for treating melanoma |
| US8835473B2 (en) * | 2004-04-16 | 2014-09-16 | Rutgers, The State University Of New Jersey | Methods and compositions for treating cancer |
| EA200801716A1 (ru) * | 2006-01-18 | 2009-04-28 | Амген Инк. | Тиазольные соединения и их применение |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
-
2010
- 2010-10-12 US US13/501,387 patent/US20120202822A1/en not_active Abandoned
- 2010-10-12 CN CN2010800564396A patent/CN102665720A/zh active Pending
- 2010-10-12 EA EA201270537A patent/EA020965B1/ru not_active IP Right Cessation
- 2010-10-12 WO PCT/US2010/052242 patent/WO2011046894A1/en not_active Ceased
- 2010-10-12 MX MX2012004259A patent/MX2012004259A/es active IP Right Grant
- 2010-10-12 JP JP2012534272A patent/JP2013507442A/ja not_active Ceased
- 2010-10-12 EP EP20100823916 patent/EP2488184A4/en not_active Withdrawn
- 2010-10-12 BR BR112012008519A patent/BR112012008519A2/pt not_active IP Right Cessation
- 2010-10-12 AU AU2010307043A patent/AU2010307043C1/en not_active Ceased
- 2010-10-12 KR KR1020127011760A patent/KR20120097496A/ko not_active Withdrawn
- 2010-10-12 CA CA2777561A patent/CA2777561A1/en not_active Abandoned
-
2012
- 2012-04-03 ZA ZA2012/02416A patent/ZA201202416B/en unknown
- 2012-04-05 IL IL219103A patent/IL219103A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201202416B (en) | 2012-12-27 |
| AU2010307043C1 (en) | 2014-03-13 |
| KR20120097496A (ko) | 2012-09-04 |
| CA2777561A1 (en) | 2011-04-21 |
| AU2010307043B2 (en) | 2013-10-31 |
| EP2488184A4 (en) | 2013-04-24 |
| EA201270537A1 (ru) | 2012-12-28 |
| CN102665720A (zh) | 2012-09-12 |
| JP2013507442A (ja) | 2013-03-04 |
| BR112012008519A2 (pt) | 2016-04-05 |
| AU2010307043A1 (en) | 2012-05-17 |
| IL219103A0 (en) | 2012-06-28 |
| WO2011046894A1 (en) | 2011-04-21 |
| US20120202822A1 (en) | 2012-08-09 |
| EP2488184A1 (en) | 2012-08-22 |
| EA020965B1 (ru) | 2015-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012004259A (es) | Combinacion. | |
| RU2016141569A (ru) | Комбинации | |
| NZ610746A (en) | Methods of treatment using selective bcl-2 inhibitors | |
| MX2015016592A (es) | Combinaciones de un anticuerpo anti-pd-l1 y un inhibidor de mek y/o un inhibidor de raf-b. | |
| EP4302834A3 (en) | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors | |
| CL2014000492A1 (es) | Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras | |
| UA114906C2 (uk) | Гетероциклільні сполуки як інгібітори мек | |
| EA201290149A1 (ru) | Комбинация | |
| MX2016007653A (es) | Combinaciones de trametinib, panitumumab y dabrafenib para el tratamiento del cancer. | |
| WO2014066606A8 (en) | Combination | |
| WO2007087204A3 (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia | |
| MY202114A (en) | Treatment of brain cancer | |
| PH12014500809A1 (en) | Polymorphs of arry-380, a slective herb2 inhibitor and pharmaceutical compositions containing them | |
| MX2021002256A (es) | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. | |
| WO2016109217A3 (en) | Btk inhibitors | |
| PH12013501098A1 (en) | Pharmaceutical compositions | |
| PH12017501121B1 (en) | Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors | |
| WO2014027981A3 (en) | Effervescent tablet formulations of dapoxetine and a pde5 inhibitor | |
| WO2011038380A3 (en) | Combination | |
| WO2013117503A3 (en) | Pi3k inhibitors for treating fibrotic diseases | |
| MX2012014386A (es) | Formas cristalinas de inhibidores de cinasa. | |
| SG10201407558TA (en) | Combination | |
| IN2015DN02667A (enExample) | ||
| PT3774795T (pt) | 4-(1h-imidazol-5-il)-1h-pirrolo[2,3-b]piridinas para utilização no tratamento de leucemias, linfomas e tumores sólidos | |
| EA201500882A1 (ru) | Комбинация |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |